↓ Skip to main content

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Overview of attention for article published in BMC Cancer, July 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

patent
5 patents

Citations

dimensions_citation
72 Dimensions

Readers on

mendeley
57 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Published in
BMC Cancer, July 2009
DOI 10.1186/1471-2407-9-263
Pubmed ID
Authors

Robert M Eager, C Casey Cunningham, Neil N Senzer, Joe Stephenson, Stephen P Anthony, Steven J O'Day, Gary Frenette, Anna C Pavlick, Barry Jones, Margaret Uprichard, John Nemunaitis

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 2 4%
Unknown 55 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 23%
Other 8 14%
Researcher 7 12%
Student > Master 7 12%
Student > Bachelor 4 7%
Other 9 16%
Unknown 9 16%
Readers by discipline Count As %
Medicine and Dentistry 15 26%
Biochemistry, Genetics and Molecular Biology 9 16%
Agricultural and Biological Sciences 7 12%
Chemistry 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Other 7 12%
Unknown 11 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#4,744,868
of 22,979,862 outputs
Outputs from BMC Cancer
#1,223
of 8,350 outputs
Outputs of similar age
#20,426
of 111,057 outputs
Outputs of similar age from BMC Cancer
#9
of 50 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,350 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,057 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.